About this event

  • Date and time Wed 18 Jan 2023 from 9:00am to 4:30pm
  • Location Royal Society of Medicine
  • Organised by Digital Health

Digital therapeutics (DTx) have been evolving for over a decade and promise to supplement or potentially replace some clinical therapies. Their potential value in facilitating significant benefits, such as meeting unmet patient needs, self-management of chronic conditions by patients, delivering treatment more affordably, reducing demands on clinician's time or being a non-pharmacological treatment.

Join this in-person event that will provide an up-to-date understanding of digital therapeutics and the opportunities to improve patient experience and outcomes, whilst delivering value for healthcare and supporting clinicians in providing care more effectively, safely and efficiently. It will also examine the regulatory landscape from the regulators and the experiences of innovators bringing solutions to the market, the latest designs, developments and deployment, and the potential influence and opportunities of DTx in their field of work.

During this event, you will:

  • Understand the concept of digital therapeutics and fields in which technologies are emerging
  • Learn from case studies of DTx use, the potential adaption of patient pathways and benefits to workflow
  • Develop insight into DTx requirements, evidence base, regulation and reimbursement
  • Learn how to consider the patient safety aspect of digital therapeutics

Follow us on:


We would like to thank our sponsoring partner TTP for their support of this meeting. 


View the programme

Registration, tea and coffee
Welcome and introduction

Ms Julia Manning, President-Elect, Digital Health Section, Royal Society of Medicine 

Keynote presentation

Overview of digital therapeutics

Dr Hugh Harvey, Hardian Healthcare

Session 1: Can digital therapeutics contribute to NHS improvement?

Chair: Ms Julia Manning, President-Elect, Digital Health Section, Royal Society of Medicine 

Understanding NHS needs inside and out

Dr Harpreet Sood, Vice-President, Huma Healthcare Company 

Thoughts of a chief nurse

Professor Sultan Mahmud, Director of Healthcare, BT Group PLC 

Virtual care expanded to other populations: How to make it accessible?

Mr Tony Bowden, Chief Executive Officer, Helicon Health

Tea and coffee break

Session 2: Digital therapeutics case studies

Chair: Dr Tim Ringrose, President, Digital Health Section, Royal Society of Medicine 

Pathway through pain

Dr John O'Dowd, Consultant Spinal Surgeon

Parkinsons kinetigraph

Professor Camille Carroll, Clinical Neuroscience Professor, University of Plymouth, Honorary Consultant Neurologist, University Hospitals Plymouth NHS Trust 

Artificial pancreas: Cam APS

Ms Hilary Nathan, Director of Policy and Communications and Community Engagement, UK Juvenile Diabetes Research Foundation

Keynote presentation

Transforming community care

Dr Andy Jones, Global Chief Growth Officer, Ramsay Health Care UK

Lunch break

Keynote presentation

Digital therapeutics for patient choice and support

Ms Liz Ashall-Payne, Chief Executive Office, ORCHA

Session 3: Regulation, investment and reimbursement

Chair: Dr Michelle Tempest, Digital Health Section, Royal Society of Medicine

Evolution of digital therapeutics regulation across

Ms Megan Coder, Chief Policy Officer, Digital Therapeutics Alliance 

Practical advice about digital therapeutics

Mr Ifran Hassan, Quality and Regulatory Manager, Psephos Biomedica

Transforming effectiveness and improving outcomes through closed loop models of care

Dr Hakin Yadi, Chief Executive Officer, Closed Loop Medicine

Tea and coffee break

Session 4: Innovation for patients - ensuring engagement

Chair: Mr David Taylor, Digital Health Section, Royal Society of Medicine 

Digital therapeutics design and development for patient adherence

Mr Dan Lock, Consultant, The Technology Partnership

The Sleepio Story

Ms Heather Cook, Special Advisory, Big Health

Pharmaceutical view: Clinical trials and engagement

Ms Cristina Duran, Chief Digital Health Officer, Astra Zeneca

Session 5: Digital therapeutics debate: Barriers and facilitators, power and privacy

Chair: Mr Richard Sargeant, Managing Director and Partner, Boston Consulting Group 

Ms Liz Ashall-Payne

Mr Richard Sargeant, Managing Director and Partner at Boston Consulting Group

Ms Julia Manning, Teaching Fellow, UCL Interaction Centre, Department of Computer Science, University College London

Professor James Wilson, Professor of Philosophy, University College London

Close of meeting

Drinks reception 



Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom


Registration for this event will close on 17 January 2023 at 1:00am (BST). Late registrations will not be accepted. 

The agenda is subject to change at any time  

All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations. 

We are only able to share presentations that we have received permission to share. This is at the presenter and the RSM’s discretion. 

This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.